Therapeutic | Intetumumab |
Target | ITGAV_ITGB3 |
Heavy Chain | QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS |
Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | VelocImmune Mouse |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Centocor Inc, Janssen Biotech, Janssen-Cilag |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Malignant melanoma, Prostate cancer |
Notes |